Could Ceramides Become the New Cholesterol?
Could Ceramides Become the New Cholesterol?
复制标题
DOI：
10.1016/j.cmet.2017.12.003
复制
发表时间：
2018-02-06
期刊：
影响因子：
29
通讯作者：
Summers, Scott A.
中科院分区：
文献类型：
--
作者：
Summers, Scott A.
梅奥诊所最近推出了一种诊断测试，对血浆神经酰胺进行量化，以确定有发生重大不良心脏事件的风险的患者。通过将关于这些生物标记物神经酰胺的最新发现与围绕胆固醇的详尽文献进行比较，萨默斯旨在突出这类令人兴奋的生物活性脂类的重要进展和迫切需要的研究领域。
The Mayo Clinic recently introduced a diagnostic test that quantifies plasma ceramides in order to identify patients at risk of major adverse cardiac events. By comparing recent discoveries about these biomarker ceramides with the exhaustive body of literature surrounding cholesterol, Summers aims to highlight important advances and critically needed areas of investigation on this exciting class of bioactive lipids.